BLC
MCID: BLD134
MIFTS: 78

Bladder Cancer (BLC)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Bladder Cancer

MalaCards integrated aliases for Bladder Cancer:

Name: Bladder Cancer 56 12 52 25 73 36 54 42 15 37
Bladder Carcinoma 12 29 54 6 15 17
Bladder Cancer, Somatic 56 29 13 6
Urinary Bladder Cancer 12 25 73 15
Malignant Neoplasm of Urinary Bladder 71
Urothelial Carcinoma of the Bladder 73
Malignant Tumor of Urinary Bladder 25
Carcinoma of Urinary Bladder 12
Urinary Bladder Neoplasms 43
Cancer of the Bladder 25
Tumor of the Bladder 12
Carcinoma of Bladder 71
Bladder Neoplasm 71
Cancer, Bladder 39
Bladder Tumors 54
Bladder Tumor 17
Blc 73

Characteristics:

OMIM:

56
Inheritance:
somatic mutation


HPO:

31
bladder cancer:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:11054 DOID:4007
OMIM 56 109800
KEGG 36 H00022
ICD9CM 34 188 188.9
MeSH 43 D001749
SNOMED-CT 67 93689003
ICD10 32 C67 C67.9
MedGen 41 C0005684
SNOMED-CT via HPO 68 124975008 255109008 263681008
UMLS 71 C0005684 C0005695 C0699885

Summaries for Bladder Cancer

KEGG : 36 The urothelium covers the luminal surface of almost the entire urinary tract, extending from the renal pelvis, through the ureter and bladder, to the proximal urethra. The majority of urothelial carcinoma are bladder carcinomas, and urothelial carcinomas of the renal pelvis and ureter account for only approximately 7% of the total. Urothelial tumours arise and evolve through divergent phenotypic pathways. Some tumours progress from urothelial hyperplasia to low-grade non-invasive superficial papillary tumours. More aggressive variants arise either from flat, high-grade carcinoma in situ (CIS) and progress to invasive tumours, or they arise de novo as invasive tumours. Low-grade papillary tumors frequently show a constitutive activation of the receptor tyrosine kinase-Ras pathway, exhibiting activating mutations in the HRAS and fibroblast growth factor receptor 3 (FGFR3) genes. In contrast, CIS and invasive tumors frequently show alterations in the TP53 and RB genes and pathways. Invasion and metastases are promoted by several factors that alter the tumour microenvironment, including the aberrant expression of E-cadherins (E-cad), matrix metalloproteinases (MMPs), angiogenic factors such as vascular endothelial growth factor (VEGF).

MalaCards based summary : Bladder Cancer, also known as bladder carcinoma, is related to bladder disease and bladder urothelial carcinoma. An important gene associated with Bladder Cancer is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Bladder cancer and MicroRNAs in cancer. The drugs Metformin and Piroxicam have been mentioned in the context of this disorder. Affiliated tissues include urinary bladder, prostate and lymph node, and related phenotype is transitional cell carcinoma of the bladder.

Disease Ontology : 12 An urinary system cancer that results in malignant growth located in the urinary bladder.

Genetics Home Reference : 25 Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply without control or order. The bladder is a hollow, muscular organ in the lower abdomen that stores urine until it is ready to be excreted from the body. The most common type of bladder cancer begins in cells lining the inside of the bladder and is called transitional cell carcinoma (TCC). Bladder cancer may cause blood in the urine, pain during urination, frequent urination, or the feeling that one needs to urinate without results. These signs and symptoms are not specific to bladder cancer, however. They also can be caused by noncancerous conditions such as infections.

NIH Rare Diseases : 52 Bladder cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the bladder. Signs and symptoms of the condition may include abdominal pain, blood in the urine, fatigue, painful urination, frequent urination, incontinence, and/or weightloss. Most cases of bladder cancer occur sporadically in people with no family history of the condition. Risk factors for the condition include smoking, exposure to certain chemicals, and having chronic bladder infections. Treatment varies based on the severity of the condition and may include surgery, radiation therapy , chemotherapy , and/or biological therapy .

MedlinePlus : 42 The bladder is a hollow organ in your lower abdomen that stores urine. Bladder cancer occurs in the lining of the bladder. It is the sixth most common type of cancer in the United States. Symptoms include Blood in your urine A frequent urge to urinate Pain when you urinate Low back pain Risk factors for developing bladder cancer include smoking and exposure to certain chemicals in the workplace. People with a family history of bladder cancer or who are older, white, or male have a higher risk. Treatments for bladder cancer include surgery, radiation therapy, chemotherapy, and biologic therapy. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 73 Bladder cancer: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.

Wikipedia : 74 Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. It is... more...

More information from OMIM: 109800

Related Diseases for Bladder Cancer

Diseases in the Bladder Cancer family:

Bladder Carcinoma in Situ

Diseases related to Bladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 929)
# Related Disease Score Top Affiliating Genes
1 bladder disease 33.7 MIR221 MIR21 MIR143 FGFR3
2 bladder urothelial carcinoma 33.4 UCA1 TUG1 RB1 PVT1 KRAS HRAS
3 renal cell carcinoma, nonpapillary 32.5 ZEB2-AS1 UCA1 TUG1 TSC1 PVT1 MIR221
4 prostate cancer 32.5 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
5 lung cancer 32.5 ZEB2-AS1 UCA1 TUG1 RB1 PVT1 MIR221
6 adenocarcinoma 32.3 RB1 KRAS HRAS H19 FGFR3
7 colorectal cancer 32.3 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
8 kidney cancer 32.2 TSC1 PVT1 MIR21 HOTAIR H19
9 squamous cell carcinoma 32.2 UCA1 TUG1 RB1 HRAS HOTAIR H19
10 lung cancer susceptibility 3 32.1 TUG1 RB1 MIR21 MIR143 KRAS HRAS
11 breast cancer 32.1 UCA1 TUG1 TSC1 RB1 PVT1 MIR221
12 gastric cancer 32.1 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
13 hepatocellular carcinoma 32.1 ZEB2-AS1 UCA1 TUG1 TSC1 RB1 PVT1
14 gallbladder cancer 32.0 UCA1 TUG1 MIR143 KRAS HOTAIR H19
15 cervical cancer 31.9 UCA1 TUG1 RB1 PVT1 MIR21 MIR143
16 b-cell lymphoma 31.9 TUG1 RB1 PVT1 MIR21 HOTAIR
17 ovarian cancer 31.8 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
18 pancreatic cancer 31.8 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
19 glioblastoma multiforme 31.8 TSC1 RB1 MIR221 MIR21 MIR10B KRAS
20 myeloma, multiple 31.7 UCA1 TUG1 PVT1 MIR21 KRAS HRAS
21 sarcoma 31.7 RB1 KRAS HRAS HOTAIR FGFR3
22 melanoma 31.7 UCA1 RB1 PVT1 MIR221 MIR127 KRAS
23 esophageal cancer 31.6 UCA1 RB1 PVT1 MIR21 MIR143 MIR10B
24 rectum cancer 31.6 MIR21 MIR143 KRAS HRAS
25 endometrial cancer 31.6 UCA1 TUG1 RB1 KRAS HRAS HOTAIR
26 non-invasive bladder papillary urothelial neoplasm 31.6 FGFR3 BRINP1
27 osteogenic sarcoma 31.6 UCA1 TUG1 RB1 PVT1 HOTAIR H19
28 neuroblastoma 31.5 RB1 MIR221 MIR21 HRAS HOTAIR H19
29 pancreatic ductal adenocarcinoma 31.5 UCA1 PVT1 MIR221 MIR21 MIR143 KRAS
30 cholangiocarcinoma 31.4 UCA1 TUG1 MIR21 KRAS H19
31 lung squamous cell carcinoma 31.4 TUG1 PVT1 KRAS HRAS FGFR3
32 nasopharyngeal carcinoma 31.4 PVT1 MIR21 MIR143 MIR10B HRAS HOTAIR
33 thyroid cancer, nonmedullary, 1 31.3 MIR221 HOTAIR H19
34 appendix adenocarcinoma 31.2 KRAS HRAS
35 retinitis pigmentosa 11 31.2 UCA1 PVT1 HRAS HOTAIR
36 squamous cell carcinoma, head and neck 31.2 RB1 MIR221 MIR21 HRAS HOTAIR H19
37 glioma susceptibility 1 31.2 TUG1 MIR221 MIR21 MIR10B HRAS HOTAIR
38 astrocytoma 31.2 UCA1 PVT1 MIR21 HOTAIR H19
39 oral squamous cell carcinoma 31.2 UCA1 TUG1 MIR221 MIR21 MIR143 HRAS
40 leukemia, chronic lymphocytic 31.2 MIR221 MIR21 MIR143 MIR10B KRAS HRAS
41 small cell cancer of the lung 31.2 TUG1 RB1 MIR21 HOTAIR
42 glioma 31.1 UCA1 PVT1 MIR221 MIR21 MIR10B HOTAIR
43 urinary system disease 31.1 MIR221 MIR21 MIR143 MIR10B
44 gallbladder disease 31.1 TSC1 MIR143 KRAS HRAS
45 leukemia, chronic myeloid 31.1 UCA1 KRAS HRAS HOTAIR H19
46 ascending colon cancer 31.0 KRAS HRAS
47 intrahepatic cholangiocarcinoma 31.0 TUG1 MIR127 KRAS
48 nevus, epidermal 31.0 KRAS HRAS FGFR3
49 hematologic cancer 31.0 RB1 PVT1 MIR221 MIR21 MIR143 MIR127
50 lung benign neoplasm 31.0 RB1 KRAS HRAS

Comorbidity relations with Bladder Cancer via Phenotypic Disease Network (PDN): (show all 17)


Acute Cystitis Acute Kidney Failure
Bladder Neck Obstruction Cystitis
Cystitis Cystica Deficiency Anemia
Hydronephrosis Neutropenia
Paralytic Ileus Prostate Cancer
Prostatic Hypertrophy Radiation Cystitis
Renal Pelvis Carcinoma Ureter, Cancer of
Urethral Benign Neoplasm Urethral Stricture
Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Bladder Cancer:



Diseases related to Bladder Cancer

Symptoms & Phenotypes for Bladder Cancer

Human phenotypes related to Bladder Cancer:

31
# Description HPO Frequency HPO Source Accession
1 transitional cell carcinoma of the bladder 31 HP:0006740

Symptoms via clinical synopsis from OMIM:

56
Neoplasia:
bladder cancer
transitional cell bladder carcinoma

Clinical features from OMIM:

109800

Drugs & Therapeutics for Bladder Cancer

Drugs for Bladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 494)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2
Piroxicam Approved, Investigational Phase 4 36322-90-4 5280452 54676228
3
Lornoxicam Approved, Investigational Phase 4 70374-39-9 5282204
4
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
5
Ofloxacin Approved Phase 4 82419-36-1 4583
6
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
7
Gliclazide Approved Phase 4 21187-98-4 3475
8
Glyburide Approved Phase 4 10238-21-8 3488
9
Glimepiride Approved Phase 4 93479-97-1 3476
10
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
11
Nicotine Approved Phase 4 54-11-5 942 89594
12
Tranexamic Acid Approved Phase 4 1197-18-8 5526
13
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
14
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
15
Parecoxib Approved Phase 4 198470-84-7
16
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
17
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
18
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
19
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
20
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
21
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
22
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
23
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
24
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
25
Fibrinolysin Investigational Phase 4 9004-09-5
26 Hypoglycemic Agents Phase 4
27 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
28 Renal Agents Phase 4
29 Anti-Infective Agents, Urinary Phase 4
30 Solifenacin succinate Phase 4 242478-38-2
31 Cephalosporins Phase 4
32 Psychotropic Drugs Phase 4
33 Cyclooxygenase 2 Inhibitors Phase 4
34 Cytochrome P-450 Enzyme Inhibitors Phase 4
35 Plasminogen Phase 4
36 Central Nervous System Stimulants Phase 4
37 Nicotinic Agonists Phase 4
38 Antifibrinolytic Agents Phase 4
39 Dopamine Uptake Inhibitors Phase 4
40 Dopamine Agents Phase 4
41 Antidepressive Agents Phase 4
42 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
43 lysine Phase 4
44 Carotenoids Phase 4
45 retinol Phase 4
46 Retinol palmitate Phase 4
47 Provitamins Phase 4
48 Adrenergic alpha-Antagonists Phase 4
49 Adrenergic Antagonists Phase 4
50 Adrenergic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 1193)
# Name Status NCT ID Phase Drugs
1 Chemoradiotherapy for Recurrent T1G3 Bladder Cancer After BCG Failure Unknown status NCT03274284 Phase 4
2 The Assessment of Postoperative Cognitive Dysfunction After Transurethral Resection of Bladder Tumor Under Spinal Anesthesia Unknown status NCT03029676 Phase 4 benzodiazepines;opioid
3 Solifenacin vs Levofloxacin vs Lornoxicam for Management of Intravesical Instillation of Bacillus Calmette-Guerin (BCG) Side Effects A Single Blinded Randomised Controlled Study Unknown status NCT03038321 Phase 4 sofenacin;Tavanic;Xefo
4 Ultrasound-Guided Obturator Nerve Block for Transurethral Procedures - Interadductor Approach Unknown status NCT02696733 Phase 4 lidocaine 2%;0.9% Natrium Chloratum with a 2nd generation cephalosporin
5 Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy and Bladder Substitutions: A Randomized Controlled Trial Unknown status NCT03147586 Phase 4 Bio-tech and omega-3 plus;placebo
6 Comparation the Effect of C-LMA and I-gel in Regurgitation and Postoperative Complications Unknown status NCT01876836 Phase 4
7 Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin. Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
8 The Value of Immediate Post-operative Intravesical Epirubicin Instillation in Intermediate and High Risk Non Muscle Invasive Bladder Cancer (NMIBC): A Randomized Controlled Trial Completed NCT02214602 Phase 4 Epirubicin
9 Comparison of Obturator Nerve Blockade and Neuromuscular Blockade for the Prevention of Adductor Spasm in Patients Undergoing Transurethral Resection of Bladder Tumors. Completed NCT03063255 Phase 4 Obturator block;Neuromuscular block
10 In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both? Completed NCT03174912 Phase 4
11 The Effect of Neuromuscular Blockade During Transurethral Resection of Bladder Cancer on Surgical Condition and Recovery Profiles : A Prospective, Randomized and Controlled Trial Completed NCT03039543 Phase 4 Rocuronium;Sugammadex
12 Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer. Completed NCT02001857 Phase 4 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.
13 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
14 Safety and Efficacy of Intravenous Tranexamic Acid in Reducing Blood Transfusion After Endoscopic Transurethral Resections in Urology: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT02653261 Phase 4 Tranexamic Acid;Placebo
15 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
16 Efficacy and Tolerance of Parecoxib for Prevention of Catheter-related Bladder Discomfort in Patients Undergoing Catheterization After TURBT: A Prospective, Randomized, Placebo-controlled, Double-blind Study Completed NCT02729935 Phase 4 Parecoxib;Placebo
17 Caret and Retinol Efficacy Trial: The Caret Coordinating Center Completed NCT00712647 Phase 4 Beta Carotene and Retinol
18 A Simple Oral Nutrition Protocol Reduces Length of Stay in Patients With Regular Radical Cystectomy Completed NCT01777126 Phase 4
19 Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression Recruiting NCT02443844 Phase 4 Tamsulosin
20 Impact of Hyperoncotic Albumin to Support Blood Loss Replacement on Plasma Volume Expansion in Cystectomy Patients. Recruiting NCT03848507 Phase 4 albumin 20%
21 The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in Cystoscopy Recruiting NCT03831321 Phase 4 Diclofenac Sodium;Lubricant Gel
22 A Phase IV Investigation of Sugammadex in Outpatient Urological Procedures Active, not recruiting NCT03138967 Phase 4 Rocuronium;Sugammadex;Neostigmine;Glycopyrrolate
23 Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC Active, not recruiting NCT03348969 Phase 4 Mitomycin c
24 Comparison of the Pathological Stage and Clinical Outcome of en Bloc Transurethral Resection by HybridKnife or Laser Versus Conventional Transurethral Resection for NMIBC: a Prospective, Single Centre, Randomized Study Not yet recruiting NCT03221062 Phase 4
25 The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer Not yet recruiting NCT03790384 Phase 4 Mitomycin
26 Must Aspirin be Discontinued Prior to TURBT: a Prospective, Randomized, Non-inferiority Trial Comparing Peri-operative Aspirin Continuation Versus Discontinuation. Terminated NCT02350543 Phase 4 Aspirin
27 Recurrence of Bladder Cancer After Transurethral Resection With Hexvix Withdrawn NCT00785694 Phase 4 hexaminolevulinate
28 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
29 A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT) Unknown status NCT02695771 Phase 3 Mitomycin C;Gemcitabine
30 Phase III Randomized Study of a Single Adjunctive Instillation of Intravesical AD 32 (N-Trifluoroacetyladriamycin-14-valerate) Versus No Adjunctive Therapy Immediately Following Transurethral Resection in Patients With Multiple Superficial (Ta/T1) Bladder Tumors Unknown status NCT00003725 Phase 3 valrubicin
31 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) Unknown status NCT00553124 Phase 3 selenium;vitamin E
32 Using Biploar Technology for Transurethral Resection of Bladder Tumor - a Randomized Controlled Trial Unknown status NCT01581723 Phase 3
33 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [TREATMENT] Unknown status NCT00553345 Phase 3 selenium;vitamin E
34 Neobladder Posterior Wall Suspended With Round Ligament of Uterus After Radical Cystectomy in Female With Bladder Cancer —a Prospective Control Study Unknown status NCT01273987 Phase 2, Phase 3
35 A Study of Comparing Effects of Thulium Laser en Bloc Resection and Electrical Transurethral Resection of the Non-muscle Invasive Bladder Cancer Unknown status NCT02951078 Phase 3
36 Study of the Efficacy of Maintenance Therapy by UFT or BCG for Superficial Bladder Cancer Against Recurrence in Urological Oncology Council of Northern Tokyo: EMBARK Study Unknown status NCT01082510 Phase 3 Bacille Calmette-Guerin;uracil-tegafur
37 Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer Unknown status NCT02074189 Phase 3 Gemcitabine, Cisplatin
38 The Efficacy of Distilled Water vs Mitomycin C as a Single Dose Immediate Instillation After Transurethral Resection of Intermediate Risk, Recurrent Superficial Bladder Cancer Unknown status NCT00816075 Phase 2, Phase 3 distilled water
39 Efficacy of Diclofenac Suppositories in Prevention of Immediate Side Effects of BCG Bladder Irrigations. A Double Blind Placebo Controlled Randomized Study Unknown status NCT01542567 Phase 3 Abitren;Placebo
40 A Phase II/III, Randomised, Two-Arm, Comparison of Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With HER1 and/or HER2 Overexpressing Locally Advanced or Metastatic Bladder Cancer [LaMB] Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
41 The Impact of Early Feeding After Radical Cystectomy for Bladder Cancer Unknown status NCT01489800 Phase 3
42 Phase III Study Of Adjuvant Cisplatin-Gemcitabine Vs. Observation After Radical Cystectomy In High-Risk Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
43 HYMN: A Randomized Controlled Phase III Trial Comparing Hyperthermia Plus Mitomycin to a Second Course of Bacillus Calmette-Guerin or Standard Therapy in Patients With Recurrence of Non-Muscle Invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guerin Therapy Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
44 Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study Unknown status NCT00146276 Phase 3 gemcitabine
45 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
46 A Multi-centre Randomised Controlled Double-blinded Trial of BCG and Interferon Alpha in High Risk Superficial Bladder Cancer Completed NCT00330707 Phase 2, Phase 3 Bacillus Calmette Guerin and interferon alpha
47 A Randomised Trial of Radical Chemo/Radiotherapy vs Radiotherapy Alone in the Definitive Management of Localised Muscle Invasive TCC of the Urinary Bladder Completed NCT00330499 Phase 3 Cisplatin
48 A Phase III Blinded Study of Immediate Post TURBT Instillation of Gemcitabine Versus Saline in Patients With Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer Completed NCT00445601 Phase 3 gemcitabine hydrochloride
49 Open-label, Multi-center Study of the Efficacy and Safety of MCC in the Treatment of Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Progression and Who Are Refractory to BCG Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
50 Phase IIb/III Chemoprevention Trial of Celecoxib to Prevent Recurrence of Superficial Bladder Cancer Completed NCT00006124 Phase 2, Phase 3 celecoxib;placebo

Search NIH Clinical Center for Bladder Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


BCG Vaccine
Carboplatin
Cisplatin
CISPLATIN PWDR
doxorubicin hydrochloride liposome
Etoposide
etoposide phosphate
pembrolizumab
Thiotepa

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bladder Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bladder Cancer:
Neo-Urinary Conduit, smooth muscle cell 3D culture for bladder diseases
Embryonic/Adult Cultured Cells Related to Bladder Cancer:
Neo-Urinary Conduit PMIDs: 22136657

Cochrane evidence based reviews: urinary bladder neoplasms

Genetic Tests for Bladder Cancer

Genetic tests related to Bladder Cancer:

# Genetic test Affiliating Genes
1 Bladder Cancer, Somatic 29 FGFR3 HRAS KRAS RB1
2 Bladder Carcinoma 29

Anatomical Context for Bladder Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Cancer:

19
Urinary Bladder

MalaCards organs/tissues related to Bladder Cancer:

40
Prostate, Lymph Node, Testes, Lung, Kidney, T Cells, Endothelial

Publications for Bladder Cancer

Articles related to Bladder Cancer:

(show top 50) (show all 34569)
# Title Authors PMID Year
1
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. 56 6
10471491 1999
2
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. 61 56
25428503 2014
3
Frequent truncating mutations of STAG2 in bladder cancer. 61 56
24121789 2013
4
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. 61 56
24121791 2013
5
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. 61 56
24121792 2013
6
Genome sequencing identifies a basis for everolimus sensitivity. 61 56
22923433 2012
7
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. 61 56
21822268 2011
8
Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. 61 56
20591884 2010
9
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. 61 56
20348956 2010
10
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. 61 56
18794855 2008
11
Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. 61 56
18245469 2008
12
Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. 61 56
16465622 2006
13
Identifying distinct classes of bladder carcinoma using microarrays. 61 56
12469123 2003
14
Cytogenetics and molecular genetics of bladder cancer: a personal view. 61 56
12407698 2002
15
Familial transitional cell carcinoma. 61 56
8709350 1996
16
Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. 61 56
7757072 1995
17
Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. 61 56
8208555 1994
18
Loss of heterozygosity on chromosome 11p13 in primary bladder carcinoma. 61 56
8100210 1993
19
Clonal origin of bladder cancer. 61 56
1445507 1992
20
Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. 54 6
2181449 1990
21
Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. 61 56
2293558 1990
22
Loss of genes on the short arm of chromosome 11 in bladder cancer. 61 6
2999610 1985
23
Oncogene from human EJ bladder carcinoma is located on the short arm of chromosome 11. 61 56
6297001 1983
24
Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. 61 6
7177195 1982
25
Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. 61 56
7063039 1982
26
Familial aggregation of urothelial carcinoma. 61 56
7053069 1981
27
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. 61 56
7207618 1981
28
Transforming activity of human tumor DNAs. 61 56
6940134 1981
29
Familial factors in bladder carcinoma. 61 56
480484 1979
30
Abnormal tryptophan metabolism in a family with a history of bladder cancer. 61 56
994212 1976
31
Intravesical Gene Therapy. 61 42
31757304 2020
32
Apaziquone for Nonmuscle Invasive Bladder Cancer: Where Are We Now? 61 42
31757302 2020
33
Combination Intravesical Therapy. 61 42
31757303 2020
34
Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. 56
25722414 2015
35
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. 6
22499344 2012
36
MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. 61 46
19767219 2010
37
A microRNA expression ratio defining the invasive phenotype in bladder tumors. 61 46
18799331 2010
38
Distinct microRNA alterations characterize high- and low-grade bladder cancer. 61 46
19843843 2009
39
MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. 54 46
19593777 2009
40
Identification of novel microRNA targets based on microRNA signatures in bladder cancer. 61 46
19378336 2009
41
Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. 61 46
19487295 2009
42
MicroRNA-143 as a tumor suppressor for bladder cancer. 61 46
19157460 2009
43
Acanthosis nigricans in a child with mild osteochondrodysplasia and K650Q mutation in the FGFR3 gene. 6
18000903 2007
44
Micro-RNA profiling in kidney and bladder cancers. 61 46
17826655 2007
45
Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation. 6
17412879 2007
46
Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia. 6
16912704 2006
47
Germline mutations in HRAS proto-oncogene cause Costello syndrome. 6
16170316 2005
48
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. 6
15772091 2005
49
Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. 6
11314002 2001
50
Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. 6
11055896 2000

Variations for Bladder Cancer

ClinVar genetic disease variations for Bladder Cancer:

6 (show top 50) (show all 84) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MRE11 NM_005590.4(MRE11):c.1098+1177G>ASNV other 60645 rs369782842 11:94199802-94199802 11:94466636-94466636
2 MRE11 NM_005590.4(MRE11):c.1098+1408A>GSNV other 60646 rs200367125 11:94199571-94199571 11:94466405-94466405
3 MRE11 NM_005590.4(MRE11):c.1098+1620T>CSNV other 60647 rs397509352 11:94199359-94199359 11:94466193-94466193
4 MRE11 NM_005590.4(MRE11):c.*1359T>CSNV other 60639 rs397509348 11:94151932-94151932 11:94418766-94418766
5 MRE11 NM_005590.4(MRE11):c.*2731G>ASNV other 60640 rs397509349 11:94150560-94150560 11:94417394-94417394
6 MRE11 NM_005590.4(MRE11):c.*570A>CSNV other 60641 rs397509346 11:94152721-94152721 11:94419555-94419555
7 MRE11 NM_005590.4(MRE11):c.*631C>TSNV other 60642 rs397509347 11:94152660-94152660 11:94419494-94419494
8 MRE11 NM_005590.4(MRE11):c.1098+614C>TSNV other 60648 rs140067184 11:94200365-94200365 11:94467199-94467199
9 MRE11 NM_005590.4(MRE11):c.1225+40T>CSNV other 60650 rs192979170 11:94197239-94197239 11:94464073-94464073
10 MRE11 NM_005590.4(MRE11):c.1225+572A>TSNV other 60651 rs397509353 11:94196707-94196707 11:94463541-94463541
11 MRE11 NM_005590.4(MRE11):c.1225+577A>CSNV other 60652 rs397509354 11:94196702-94196702 11:94463536-94463536
12 MRE11 NM_005590.4(MRE11):c.1225+605T>CSNV other 60653 rs397509355 11:94196674-94196674 11:94463508-94463508
13 MRE11 NM_005590.4(MRE11):c.1225+804T>CSNV other 60654 rs397509356 11:94196475-94196475 11:94463309-94463309
14 MRE11 NM_005590.4(MRE11):c.1327-461A>CSNV other 60655 rs185485357 11:94193208-94193208 11:94460042-94460042
15 MRE11 NM_005590.4(MRE11):c.1783+561G>ASNV other 60656 rs397509357 11:94179824-94179824 11:94446658-94446658
16 MRE11 NM_005590.4(MRE11):c.1783+888A>GSNV other 60657 rs397509358 11:94179497-94179497 11:94446331-94446331
17 MRE11 NM_005590.4(MRE11):c.20+821G>ASNV other 60658 rs397509351 11:94225127-94225127 11:94491961-94491961
18 MRE11 NM_005590.4(MRE11):c.314+99A>GSNV other 60659 rs143677623 11:94218991-94218991 11:94485825-94485825
19 MRE11 NM_005590.4(MRE11):c.545-297G>TSNV other 60660 rs118024137 11:94209866-94209866 11:94476700-94476700
20 MRE11 NM_005590.4(MRE11):c.1563+281G>ASNV other 60672 rs397509429 11:94189161-94189161 11:94455995-94455995
21 MRE11 NM_005590.4(MRE11):c.-105-326A>TSNV other 60643 rs183829476 11:94226398-94226398 11:94493232-94493232
22 MRE11 NM_005590.4(MRE11):c.-105-387C>TSNV other 60644 rs397509350 11:94226459-94226459 11:94493293-94493293
23 RB1 NM_000321.2(RB1):c.1981C>T (p.Arg661Trp)SNV Pathogenic 13087 rs137853294 13:49033844-49033844 13:48459708-48459708
24 RB1 NM_000321.2(RB1):c.2107-2A>GSNV Pathogenic 13077 13:49037865-49037865 13:48463729-48463729
25 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
26 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
27 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
28 HRAS NM_005343.4(HRAS):c.35G>T (p.Gly12Val)SNV Pathogenic 12600 rs104894230 11:534288-534288 11:534288-534288
29 FGFR3 NM_000142.4(FGFR3):c.1949A>C (p.Lys650Thr)SNV Pathogenic 65855 rs121913105 4:1807890-1807890 4:1806163-1806163
30 RB1 NM_000321.2(RB1):c.1215+1G>ASNV Pathogenic 126832 rs587776783 13:48947629-48947629 13:48373493-48373493
31 KRAS NM_033360.4(KRAS):c.34G>C (p.Gly12Arg)SNV Pathogenic 12579 rs121913530 12:25398285-25398285 12:25245351-25245351
32 KRAS NM_033360.4(KRAS):c.*12A>TSNV Pathogenic 12587 rs104894360 12:25362838-25362838 12:25209904-25209904
33 FGFR3 NM_000142.4(FGFR3):c.742C>T (p.Arg248Cys)SNV Pathogenic 16332 rs121913482 4:1803564-1803564 4:1801837-1801837
34 FGFR3 NM_000142.4(FGFR3):c.1111A>T (p.Ser371Cys)SNV Pathogenic 16333 rs121913484 4:1806092-1806092 4:1804365-1804365
35 FGFR3 NM_000142.4(FGFR3):c.1620C>G (p.Asn540Lys)SNV Pathogenic 16338 rs28933068 4:1807371-1807371 4:1805644-1805644
36 FGFR3 NM_000142.4(FGFR3):c.746C>G (p.Ser249Cys)SNV Pathogenic 16339 rs121913483 4:1803568-1803568 4:1801841-1801841
37 FGFR3 NM_000142.4(FGFR3):c.749C>G (p.Pro250Arg)SNV Pathogenic 16340 rs4647924 4:1803571-1803571 4:1801844-1801844
38 FGFR3 NM_000142.4(FGFR3):c.1108G>T (p.Gly370Cys)SNV Pathogenic 16359 rs121913479 4:1806089-1806089 4:1804362-1804362
39 TSC1 NM_000368.5(TSC1):c.1525C>T (p.Arg509Ter)SNV Pathogenic 48796 rs118203542 9:135781440-135781440 9:132906053-132906053
40 TSC1 NM_001162426.2(TSC1):c.1902_1903AG[1] (p.Glu635fs)short repeat Pathogenic 48852 rs118203599 9:135781057-135781058 9:132905670-132905671
41 TSC1 NM_000368.5(TSC1):c.2074C>T (p.Arg692Ter)SNV Pathogenic 48885 rs118203631 9:135779172-135779172 9:132903785-132903785
42 TSC1 NM_000368.4(TSC1):c.663+1G>ASNV Pathogenic/Likely pathogenic 49076 rs118203419 9:135797205-135797205 9:132921818-132921818
43 TSC1 NM_000368.4(TSC1):c.664-1G>ASNV Pathogenic/Likely pathogenic 49080 rs118203423 9:135796824-135796824 9:132921437-132921437
44 TSC1 NM_000368.4(TSC1):c.1579C>T (p.Gln527Ter)SNV Pathogenic/Likely pathogenic 48804 rs118203549 9:135781386-135781386 9:132905999-132905999
45 FGFR3 NM_000142.4(FGFR3):c.2089G>T (p.Gly697Cys)SNV Likely pathogenic 376248 rs121913480 4:1808331-1808331 4:1806604-1806604
46 RB1 NM_000321.2(RB1):c.269G>T (p.Gly90Val)SNV Conflicting interpretations of pathogenicity 458158 rs554727080 13:48916739-48916739 13:48342603-48342603
47 RB1 NM_000321.2(RB1):c.850A>G (p.Asn284Asp)SNV Conflicting interpretations of pathogenicity 458185 rs761609284 13:48937082-48937082 13:48362946-48362946
48 TSC1 NM_000368.4(TSC1):c.1250C>T (p.Thr417Ile)SNV Conflicting interpretations of pathogenicity 48752 rs77464996 9:135785971-135785971 9:132910584-132910584
49 FGFR3 NM_000142.4(FGFR3):c.1948A>C (p.Lys650Gln)SNV Conflicting interpretations of pathogenicity 16348 rs78311289 4:1807889-1807889 4:1806162-1806162
50 FGFR3 NM_000142.4(FGFR3):c.1118A>G (p.Tyr373Cys)SNV Conflicting interpretations of pathogenicity 16342 rs121913485 4:1806099-1806099 4:1804372-1804372

UniProtKB/Swiss-Prot genetic disease variations for Bladder Cancer:

73
# Symbol AA change Variation ID SNP ID
1 FGFR3 p.Arg248Cys VAR_004148 rs121913482
2 FGFR3 p.Ser249Cys VAR_004149 rs121913483
3 FGFR3 p.Gly370Cys VAR_004151 rs121913479
4 FGFR3 p.Lys650Glu VAR_004160 rs78311289
5 FGFR3 p.Lys650Gln VAR_018390 rs78311289

Cosmic variations for Bladder Cancer:

9 (show top 50) (show all 23555)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263080 ZRSR2 urinary tract,bladder,carcinoma,transitional cell carcinoma c.946G>C p.E316Q 23:15822739-15822739 4
2 COSM88263088 ZRSR2 urinary tract,bladder,carcinoma,transitional cell carcinoma c.965G>A p.R322K 23:15822758-15822758 4
3 COSM149314765 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.9829C>T p.P3277S 16:72788447-72788447 4
4 COSM149282136 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.8029G>A p.E2677K 16:72794653-72794653 4
5 COSM149332078 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.11065A>T p.K3689* 16:72787211-72787211 4
6 COSM149268190 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.5645T>A p.I1882N 16:72797037-72797037 4
7 COSM149297301 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.9812C>T p.T3271M 16:72788464-72788464 4
8 COSM149318900 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.5416G>C p.E1806Q 16:72797266-72797266 4
9 COSM149321603 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.9964C>T p.Q3322* 16:72788312-72788312 4
10 COSM149317827 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.554C>T p.S185L 16:72959592-72959592 4
11 COSM149265910 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.8849G>A p.R2950H 16:72793833-72793833 4
12 COSM149262739 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.8376G>A p.M2792I 16:72794306-72794306 4
13 COSM149304877 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.4880C>T p.A1627V 16:72797802-72797802 4
14 COSM149297628 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.8711A>G p.K2904R 16:72793971-72793971 4
15 COSM149294302 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.9127A>G p.I3043V 16:72793555-72793555 4
16 COSM149262746 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.808G>A p.D270N 16:72959338-72959338 4
17 COSM149318895 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.7576C>T p.Q2526* 16:72795106-72795106 4
18 COSM149332025 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.625G>A p.E209K 16:72959521-72959521 4
19 COSM149298321 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.6608G>A p.R2203H 16:72796074-72796074 4
20 COSM149319996 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.151G>A p.D51N 16:72959995-72959995 4
21 COSM149306658 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.10573G>A p.G3525S 16:72787703-72787703 4
22 COSM149287730 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.2458C>T p.R820C 16:72957688-72957688 4
23 COSM149303763 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.2249A>G p.H750R 16:72957897-72957897 4
24 COSM149331635 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.883C>T p.R295C 16:72959263-72959263 4
25 COSM149318889 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.8390G>T p.R2797I 16:72794292-72794292 4
26 COSM149275988 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.4937C>T p.S1646F 16:72797745-72797745 4
27 COSM149304885 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.4817G>A p.S1606N 16:72797865-72797865 4
28 COSM149283576 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.6910C>T p.Q2304* 16:72795772-72795772 4
29 COSM149290589 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.10826C>T p.S3609F 16:72787450-72787450 4
30 COSM149269782 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.4595A>G p.N1532S 16:72798087-72798087 4
31 COSM149301400 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.2434G>C p.E812Q 16:72957712-72957712 4
32 COSM149301409 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.1907C>T p.S636L 16:72958239-72958239 4
33 COSM149280992 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.7799C>G p.S2600* 16:72794883-72794883 4
34 COSM149286797 ZFHX3 urinary tract,urethra,carcinoma,adenocarcinoma c.8649G>T p.M2883I 16:72794033-72794033 4
35 COSM149319982 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.7253C>T p.T2418I 16:72795429-72795429 4
36 COSM149304868 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.5886G>T p.E1962D 16:72796796-72796796 4
37 COSM149322707 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.10802C>T p.S3601L 16:72787474-72787474 4
38 COSM149268207 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.308G>A p.R103H 16:72959838-72959838 4
39 COSM149304853 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.10403G>A p.R3468H 16:72787873-72787873 4
40 COSM149278204 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.2230C>T p.H744Y 16:72957916-72957916 4
41 COSM149301339 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.49G>A p.G17S 16:72960097-72960097 4
42 COSM149319969 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.10015G>C p.E3339Q 16:72788261-72788261 4
43 COSM152022231 YES1 urinary tract,bladder,carcinoma,transitional cell carcinoma c.460C>G p.Q154E 18:747930-747930 4
44 COSM152021895 YES1 urinary tract,bladder,carcinoma,transitional cell carcinoma c.1342C>T p.R448W 18:732915-732915 4
45 COSM152021892 YES1 urinary tract,bladder,carcinoma,transitional cell carcinoma c.595C>T p.R199C 18:745837-745837 4
46 COSM143034592 YAP1 urinary tract,bladder,carcinoma,transitional cell carcinoma c.182C>G p.S61W 11:102111030-102111030 4
47 COSM143037377 YAP1 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.1260C>A p.F420L 11:102227553-102227553 4
48 COSM97252210 XRCC2 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.151G>A p.G51R 7:152649334-152649334 4
49 COSM101975701 XPO1 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.1711G>A p.E571K 2:61492337-61492337 4
50 COSM101976237 XPO1 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.1525C>T p.H509Y 2:61492608-61492608 4

Copy number variations for Bladder Cancer from CNVD:

7 (show top 50) (show all 98)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 75136 13 16000000 114142980 Copy number Bladder cancer
2 80757 13 97270228 100084626 Gain Bladder cancer
3 87829 14 77750645 79747731 Loss Bladder cancer
4 89915 15 19427350 19427409 Loss Bladder cancer
5 96847 15 95052889 95403459 Loss Bladder cancer
6 121742 18 467310 796252 Gain Bladder cancer
7 122814 18 61643142 67432063 Loss Bladder cancer
8 127148 19 278073 12616127 Gain Bladder cancer
9 135959 2 123437325 126399586 Loss Bladder cancer
10 138231 2 159948195 160120757 Loss Bladder cancer
11 141850 2 217249378 242464793 Loss Bladder cancer
12 147190 2 60966923 61033726 Loss Bladder cancer
13 171019 3 162425422 164314793 Gain Bladder cancer
14 176797 3 50653920 52539982 Loss Bladder cancer
15 186746 4 38697312 42182524 Loss Bladder cancer
16 205260 6 123251233 125408147 Loss Bladder cancer
17 211927 6 352263 9584745 Loss Bladder cancer
18 220303 7 137295729 140266986 Gain Bladder cancer
19 222347 7 151407323 152089322 Gain Bladder cancer
20 242699 8 73900000 106200000 Gain Bladder cancer
21 263059 X 46203719 47229186 Gain Bladder cancer
22 263791 X 53475704 54578960 Gain Bladder cancer
23 264448 X 6562512 8075294 Gain Bladder cancer
24 250746 9 21968346 21998655 Loss Bladder cancer
25 250059 9 19900000 33200000 Loss Bladder cancer
26 248424 9 135189457 138807183 Loss Bladder cancer
27 246038 9 115832220 122222082 Loss Bladder cancer
28 241511 8 6248230 9674346 Loss Bladder cancer
29 239544 8 39378051 39505315 Loss Bladder cancer
30 239543 8 39377851 39505456 Gain Bladder cancer
31 237886 8 27400000 45600000 Loss Bladder cancer
32 237104 8 211611 432326 Loss Bladder cancer
33 234901 8 13991707 31607745 Loss Bladder cancer
34 231315 8 103489656 104289922 Gain Bladder cancer
35 229961 7 97323707 104995507 Gain Bladder cancer
36 226961 7 63642906 76078892 Gain Bladder cancer
37 225293 7 4475515 6837609 Gain Bladder cancer
38 224960 7 39813709 40099186 Gain Bladder cancer
39 223613 7 23201784 23537259 Gain Bladder cancer
40 222601 7 15397545 19006302 Gain Bladder cancer
41 219665 7 128677670 129696226 Gain Bladder cancer
42 213590 6 48489133 52026397 Loss Bladder cancer
43 213172 6 43589125 44077743 Gain Bladder cancer
44 207124 6 15200000 25200000 Amplification Bladder cancer
45 204477 6 11110371 17397320 Gain Bladder cancer
46 204292 6 108783383 109034288 Loss Bladder cancer
47 204149 6 107127877 107503845 Loss Bladder cancer
48 203715 6 1 61000000 Gain Bladder cancer
49 202946 5 90316808 90788310 Loss Bladder cancer
50 200115 5 50094582 74360979 Loss Bladder cancer

Expression for Bladder Cancer

Search GEO for disease gene expression data for Bladder Cancer.

Pathways for Bladder Cancer

Pathways related to Bladder Cancer according to KEGG:

36
# Name Kegg Source Accession
1 Bladder cancer hsa05219
2 MicroRNAs in cancer hsa05206

GO Terms for Bladder Cancer

Biological processes related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.73 MIR221 MIR21 MIR143 MIR10B
2 negative regulation of cell proliferation GO:0008285 9.72 TSC1 RB1 MIR221 MIR21 HRAS
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.67 MIR221 MIR21 HRAS FGFR3
4 Ras protein signal transduction GO:0007265 9.58 RB1 KRAS HRAS
5 positive regulation of protein kinase B signaling GO:0051897 9.46 MIR221 MIR21 MIR143 FGFR3
6 response to isolation stress GO:0035900 9.26 KRAS HRAS
7 negative regulation of GTPase activity GO:0034260 9.13 TSC1 MIR21 HRAS
8 positive regulation of vascular associated smooth muscle cell migration GO:1904754 8.8 MIR221 MIR21 MIR143

Molecular functions related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR221 MIR21 MIR143 MIR10B

Sources for Bladder Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....